## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A compound of the formula I,

١

in which

A)

R1 to R4 are H;

X is  $S_{,} SO_{,} SO_{2}$ ;

Y is  $(CH_2)_p$ , where p is 0, 1, 2 or 3;

is CF<sub>3</sub>, (C<sub>2</sub>-C<sub>18</sub>)-alkyl, (C<sub>3</sub>-C<sub>4</sub>)-cycloalkyl, (C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, wherein the alkyl or cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

 $(CH_2)_r$ -COR6, where r is 1-6 and R6 is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

 $CH_2$ -CH(NHR7)-COR8, where R7 is H, C(O)- $(C_1$ - $C_4)$ -alkyl or C(O)O- $(C_1$ - $C_4)$ -alkyl and R8 is OH, O- $(C_1$ - $C_6)$ -alkyl or  $NH_2$ ;

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

phenyl, 1- or 2-naphthyl, <u>or</u> biphenyl <del>or a heterocyclic</del> radical, where the rings or ring systems are substituted one or two times by <u>F, Cl, Br, I, CN,</u>  $O(C_1-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -

with the proviso that R5 is not unsubstituted phenyl, 4-fluorophenyl, 4-bromophenyl, 4-chlorophenyl, 3-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-n-butylphenyl, 4-t-butylphenyl, 2-aminophenyl, 2- $\frac{1}{2}$ -alkyl;

or

B)

ij

R1, R4 independently of one another are

H, F, Cl, Br, I, CN, N<sub>3</sub>, NO<sub>2</sub>, OH, O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O(C<sub>3</sub>-C<sub>4</sub> and C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-phenyl, O-phenyl, O-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>8</sub>)-alkyl, S(O)<sub>0-2</sub>(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH<sub>-</sub>(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH<sub>-</sub>(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH<sub>-</sub>(C<sub>3</sub>-C<sub>8</sub>

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LL

CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, SO<sub>2</sub>-NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH-SO<sub>2</sub>-NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-SO<sub>2</sub>-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-COOH, O-CH<sub>2</sub>-CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-H<sub>2</sub>-COOH, CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-O-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, CO-NH<sub>2</sub>, CO-NH(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>,

 $(C_1-C_8)$ -alkyl,  $(C_3-C_8)$ -cycloalkyl,  $(C_2-C_8)$ -alkenyl, or  $(C_2-C_8)$ -alkynyl, where in the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine,

or one hydrogen replaced by OH, OC(O)CH<sub>3</sub>, O-CH<sub>2</sub>-Ph, NH<sub>2</sub>, NH-CO-CH<sub>3</sub> or N(COOCH<sub>2</sub>Ph)<sub>2</sub>; or

phenyl, or 1- or 2-naphthyl,

5-tetrazolyl, 1-[( $C_4$ - $C_6$ )-alkyl]-5-tetrazolyl, 2-[( $C_4$ - $C_6$ )-alkyl]-5-tetrazolyl;

1-imidazolyl;

1- or 4-[1,2,4]-triazolyl,

2- or 3-thienyl,

2- or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

3-, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl, or

3-, 4- or 5-isothiazolyl

where in each case the aryl radical <del>or heterocycle</del> is unsubstituted or substituted one or two times by

F, Cl, Br, CN,

OH,  $(C_1-C_4)$ -alkyl,  $CF_3$ ,  $O-(C_1-C_4)$ -alkyl,

S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COOH, CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or CO-NH<sub>2</sub> and in the alkyl groups one to seven hydrogen atoms may be replaced by fluorine;

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER !!!

## R2, R3 independently of one another are

H, F, Cl, Br, I, CN, N<sub>3</sub>, NO<sub>2</sub>, O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, O-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>8</sub>)-alkyl, S(O)<sub>0-2</sub>(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, N[(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl]<sub>2</sub>, NH-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>-NH-(C<sub>5</sub>-C<sub>8</sub>)-alkyl, SO<sub>2</sub>-NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-SO<sub>2</sub>-(C<sub>5</sub>-C<sub>8</sub>)-cycloalkyl; O-CH<sub>2</sub>-COOH, O-CH<sub>2</sub>-CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, COOH, CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-O-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, CO-NH(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, (C<sub>2</sub>-C<sub>8</sub>)-alkenyl, or (C<sub>2</sub>-C<sub>8</sub>)-alkynyl, where in the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine, or one hydrogen replaced by OH, OC(O)CH<sub>3</sub>, O-CH<sub>2</sub>-Ph, NH<sub>2</sub>, NH-CO-CH<sub>3</sub> or N(COOCH<sub>2</sub>Ph)<sub>2</sub>; or

phenyl, or 1- or 2-naphthyl, 5-tetrazolyl, 1- $[(C_1-C_6)$ -alkyl]-5-tetrazolyl, 2- $[(C_1-C_6)$ -alkyl]-5-tetrazolyl; 1-imidazolyl; 1-or 4-[1,2,4]-triazolyl, 2-or 3-thienyl, 2-or 3-furyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-thiazolyl,

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

3-, 4- or 5-isothiazolyl

where the heterocycle is unsubstituted or substituted one or two times by F, CI, Br, CN, OH,  $(C_1-C_4)$ -alkyl,  $CF_3$ , O- $(C_4-C_4)$ -alkyl,  $S(O)_{0-2}(C_1-C_6)$ -alkyl,  $NH_2$ , NH- $SO_2$ - $(C_4-C_4)$ -alkyl, COOH, CO-O- $(C_4-C_4)$ -alkyl or CO- $NH_2$ -and-wherein in the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or R2 and R3 together form the group –O-CH<sub>2</sub>-O-; where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;

X is  $S_{,} SO_{,} SO_{2}$ ;

ij

Y is  $(CH_2)_p$ , where p can be is 0, 1, 2 or 3;

R5 is (C<sub>1</sub>-C<sub>18</sub>)-alkyl or (C<sub>3</sub>-C<sub>4</sub>- and C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, wherein the alkyl and cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

 $(CH_2)_r$ -COR6, where r is 1-6 and R6 is OH, O- $(C_1$ -C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

CH<sub>2</sub>-CH(NHR7)-COR8, where R7 is H, C(O)-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or C(O)O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and R8 is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

phenyl, 1- or 2-naphthyl, <u>or</u> biphenyl <del>or a heterocyclic radical</del>, where the rings or ring systems can be substituted up to two times by <u>F</u>, <u>Cl</u>, <u>Br</u>, <u>I</u>, <u>CN</u>,  $O(C_1-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_1-C_8)$ -alkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O(C_3-C_8)$ -cycloalkyl

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER !!!

Customer No. 22,852 Attorney Docket No. 2481.1799-01

alkyl, NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, N[(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl]<sub>2</sub>, NH-CO-(C<sub>2</sub>-C<sub>8</sub>)-alkyl, NH-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, SO<sub>2</sub>-NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH-SO<sub>2</sub>-NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-SO<sub>2</sub>-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-COOH, O-CH<sub>2</sub>-CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, COOH, CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-O-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, CO-NH<sub>2</sub>, CO-NH(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, or (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, where in the alkyl or cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine; or F. Cl. Br. I. or CN;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

- 2. (Currently Amended) The compound as claimed in claim 1, in which
- R1, R4 independently of one another are

H, F, CI, Br, I, CN, N<sub>3</sub>, NO<sub>2</sub>, OH, O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O(C<sub>3</sub>-C<sub>4</sub> and C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-phenyl, O-phenyl, O-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>8</sub>)-alkyl, S(O)<sub>0-2</sub>(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, N[(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl]<sub>2</sub>, NH-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, SO<sub>2</sub>-NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH-SO<sub>2</sub>-NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-SO<sub>2</sub>-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-COOH, O-CH<sub>2</sub>-CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, COOH, CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-O-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, CO-NH<sub>2</sub>, CO-NH(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, (C<sub>2</sub>-C<sub>8</sub>)-alkyl, or (C<sub>2</sub>-C<sub>8</sub>)-alkynyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP li

fluorine, or one hydrogen replaced by OH, OC(O)CH<sub>3</sub>, O-CH<sub>2</sub>-Ph, NH<sub>2</sub>, NH-CO-CH<sub>3</sub> or N(COOCH<sub>2</sub>Ph)<sub>2</sub>; or

phenyl, or 1- or 2-naphthyl,

 $\textcolor{red}{5-tetrazolyl, 1-[(C_4-C_6)-alkyl]-5-tetrazolyl, 2-[(C_4-C_6)-alkyl]-5-tetrazolyl;}$ 

1-imidazolyl;

1-or 4-[1,2,4]-triazolyl,

2- or 3-thienyl,

2-or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

3, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl,

3-, 4- or 5-isothiazolyl

where in each case the aryl radical <del>or heterocycle</del> is unsubstituted or substituted one or two times by

F, Cl, Br, CN,

OH,  $(C_1-C_4)$ -alkyl,  $CF_3$ ,  $O-(C_1-C_4)$ -alkyl,

 $S(O)_{0-2}(C_1-C_6)$ -alkyl,  $NH_2$ ,  $NH-SO_2-(C_1-C_4)$ -alkyl,

COOH, CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-NH<sub>2</sub> and wherein in the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

## R2, R3 independently of one another are

H, F, Cl, Br, I, CN, N<sub>3</sub>, NO<sub>2</sub>, O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, O-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>8</sub>)-alkyl, S(O)<sub>0-2</sub>(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, N[(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl]<sub>2</sub>, NH-CO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-CO-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER

SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>-NH-(C<sub>5</sub>-C<sub>8</sub>)-alkyl, SO<sub>2</sub>-NH-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, NH-SO<sub>2</sub>-NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, NH-SO<sub>2</sub>-(C<sub>5</sub>-C<sub>8</sub>)-cycloalkyl, O-CH<sub>2</sub>-COOH, O-CH<sub>2</sub>-CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, COOH, CO-O(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-O-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, CO-NH<sub>2</sub>, CO-NH(C<sub>1</sub>-C<sub>8</sub>)-alkyl, CO-N[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, (C<sub>2</sub>-C<sub>8</sub>)-alkenyl, or (C<sub>2</sub>-C<sub>8</sub>)-alkynyl, where in the alkyl, alkenyl cycloalkyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine, or one hydrogen replaced by OH, OC(O)CH<sub>3</sub>, O-CH<sub>2</sub>-Ph, NH<sub>2</sub>, NH-CO-CH<sub>3</sub> or N(COOCH<sub>2</sub>Ph)<sub>2</sub>; or

phenyl, or 1- or 2-naphthyl, 5-tetrazolyl, 1- $[(C_4-C_6)$ -alkyl]-5-tetrazolyl, 2- $[(C_4-C_6)$ -alkyl]-5-tetrazolyl; 1-imidazolyl; 1-or 4-[1,2,4]-triazolyl, 2-or 3-thienyl, 2-or 3-furyl, 2-, 3-or 4-pyridyl, 2-, 4-or 5-isoxazolyl, 3-, 4-or 5-isothiazolyl where the heterocycle may b

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 l Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com where the heterocycle may be substituted up to two times by

F, Cl, Br, CN, OH,  $(C_4-C_4)$ -alkyl, CF<sub>3</sub>, O- $(C_4-C_4)$ -alkyl,

S(O)<sub>0-2</sub>(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

COOH, CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-NH<sub>2</sub>-wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or R2 and R3 together form the group –O-CH<sub>2</sub>-O-; where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;

X is  $S_{7}$ ,  $SO_{7}$ ,  $SO_{2}$ ;

1

- Y is  $(CH_2)_p$ , where p can be is 0, 1, 2 or 3;
- R5 is (C<sub>1</sub>-C<sub>18</sub>)-alkyl or (C<sub>3</sub>-C<sub>4</sub>- and C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, wherein the alkyl or cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

 $(CH_2)_r$ -COR6, where r is 1-6 and R6 is OH, O- $(C_1$ -C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

CH<sub>2</sub>-CH(NHR7)-COR8, where R7 is H, C(O)-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or C(O)O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl where R8 is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

phenyl, 1- or 2-naphthyl, <u>or</u> biphenyl <del>or a heterocyclic radical</del>, where the rings or ring systems can be substituted up to two times by  $\underline{F}$ ,  $\underline{Cl}$ ,  $\underline{Br}$ ,  $\underline{l}$ ,  $\underline{CN}$ ,  $O(C_1-C_8)$ -alkyl,  $O(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_1-C_8)$ -alkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_3-C_8)$ -alkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_3-C_8)$ -alkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl,  $O-CO-(C_3-C_8)$ -cycloalkyl, O-CO-

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLL

Customer No. 22,852 Attorney Docket No. 2481.1799-01

the alkyl or cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine; or F, Cl, Br, I, or CN;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

- 3. (Currently Amended) The compound as claimed in claim 1, in which
- R1, R4 independently of one another are H, F, Cl, or Br;
- R2, R3 independently of one another are H, F, Cl, Br, CN,CONH<sub>2</sub>, NH-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, COOH, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkenyl, (C<sub>1</sub>-C<sub>8</sub>)-alkynyl, wherein the alkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine; or

phenyl, or 1-imidazolyl; where the rings may be substituted up to two times by

F, Cl, Br, CN, OH,  $(C_1-C_4)$ -alkyl, CF<sub>3</sub>, O- $(C_1-C_4)$ -alkyl, wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;

X is S<del>, SO, SO</del><sub>2</sub>;

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP ļ

Y is  $(CH_2)_p$ , where p can be is 0 or 1;

is (C<sub>1</sub>-C<sub>18</sub>)-alkyl or (C<sub>3</sub>-C<sub>4</sub>- and C<sub>6</sub>-C<sub>8</sub>)-cycloalkyl, where in the alkyl and cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

 $(CH_2)_r$ -CO-O- $(C_1$ -C<sub>6</sub>)-alkyl, where r is 1-6;

CH<sub>2</sub>-CH(NHR7)-COR8, where R7 is H, C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or C(O)O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and R8 is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>;

phenyl, a heterocyclic radical;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

- 4. (Cancelled)
- 5. (Original) The compound as claimed in claim 1, which

R1 is H,

R2 is CI,

R3 is H,

R4 is H,

R5 is CH<sub>3</sub>,

X is S, and

Y is  $(CH_2)_p$  where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

6. - 29. (Cancelled)

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER